Literature DB >> 36104630

Adverse outcome associated with daratumumab-based treatments in relapsed/refractory multiple myeloma patients with amplification of chromosome arm 1q21: a single-center retrospective experience.

Roberto Marasca1, Mario Luppi1, Emiliano Barbieri2, Monica Maccaferri1, Giovanna Leonardi1, Francesca Giacobbi1, Giorgia Corradini1, Ivana Lagreca1, Patrizia Barozzi1, Leonardo Potenza1.   

Abstract

Entities:  

Keywords:  Chromosome 1q amplification; Chromosome 1q gain/amplification; Daratumumab; Multiple myeloma; Relapsed-refractory multiple myeloma; To the editor

Year:  2022        PMID： 36104630     DOI： 10.1007/s00277-022-04978-6

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   4.030


× No keyword cloud information.
  5 in total

1.  Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

Authors:  M A Dimopoulos; P Moreau; E Terpos; M V Mateos; S Zweegman; G Cook; M Delforge; R Hájek; F Schjesvold; M Cavo; H Goldschmidt; T Facon; H Einsele; M Boccadoro; J San-Miguel; P Sonneveld; U Mey
Journal:  Ann Oncol       Date:  2021-02-03       Impact factor: 32.976

2.  Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy.

Authors:  Xiao Hu; Cherng-Horng Wu; Janet M Cowan; Raymond L Comenzo; Cindy Varga
Journal:  Ann Hematol       Date:  2021-11-08       Impact factor: 3.673

Review 3.  Chromosomal 1q21 abnormalities in multiple myeloma: a review of translational, clinical research, and therapeutic strategies.

Authors:  Kamlesh Bisht; Brian Walker; Shaji K Kumar; Ivan Spicka; Philippe Moreau; Tom Martin; Luciano J Costa; Joshua Richter; Taro Fukao; Sandrine Macé; Helgi van de Velde
Journal:  Expert Rev Hematol       Date:  2021-10-08       Impact factor: 2.929

4.  Multiple myeloma: 2022 update on diagnosis, risk stratification, and management.

Authors:  S Vincent Rajkumar
Journal:  Am J Hematol       Date:  2022-05-23       Impact factor: 13.265

5.  Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.

Authors:  Meera Mohan; Niels Weinhold; Carolina Schinke; Sharmilan Thanedrarajan; Leo Rasche; Jeffrey R Sawyer; Erming Tian; Frits van Rhee; Maurizio Zangari
Journal:  Br J Haematol       Date:  2019-12-09       Impact factor: 6.998
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.